A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).

被引：1
|
作者：
Thota, Ramya
Goff, Laura Williams
Chan, Emily
Berlin, Jordan
Jones, C. Michael
McClanahan, Pamela
Ayers, Gregory Dan
Cardin, Dana Backlund
机构：
[1] Vanderbilt Univ, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Jones Clin, Germantown, TN USA
[5] Vanderbilt Univ, Div Canc Biostat, Nashville, TN 37235 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
297
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma
    Berruti, Alfredo
    Sperone, Paola
    Ferrero, Anna
    Germano, Antonina
    Ardito, Arianna
    Priola, Adriano Massimiliano
    De Francia, Silvia
    Volante, Marco
    Daffara, Fulvia
    Generali, Daniele
    Leboulleux, Sophie
    Perotti, Paola
    Baudin, Eric
    Papotti, Mauro
    Terzolo, Massimo
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (03) : 451 - 458
  • [42] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [43] A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer
    Choi, Dae Ro
    Yoon, Sang Nam
    Kim, Hyeong Su
    Kim, Jung Han
    Kim, Kwang Yong
    Kim, Byung Chun
    Choi, Young Kyun
    Kim, Jin Bae
    Han, Boram
    Song, Hun Ho
    Zang, Dae Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 639 - 643
  • [44] A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer
    Dae Ro Choi
    Sang Nam Yoon
    Hyeong Su Kim
    Jung Han Kim
    Kwang Yong Kim
    Byung Chun Kim
    Young Kyun Choi
    Jin Bae Kim
    Boram Han
    Hun Ho Song
    Dae Young Zang
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 639 - 643
  • [45] A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
    Decker, Thomas
    Overkamp, Friedrich
    Roesel, Siegfried
    Nusch, Arnd
    Goehler, Thomas
    Indorf, Martin
    Sahlmann, Joerg
    Trarbach, Tanja
    BMC CANCER, 2017, 17
  • [46] Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
    Jones, S
    Vogel, C
    Arkhipov, A
    Fehrenbacher, L
    Eisenberg, P
    Cooper, B
    Honig, S
    Polli, A
    Whaley, F
    di Salle, E
    Tiffany, J
    Consonni, A
    Miller, L
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3418 - 3425
  • [47] A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
    Thomas Decker
    Friedrich Overkamp
    Siegfried Rösel
    Arnd Nusch
    Thomas Göhler
    Martin Indorf
    Jörg Sahlmann
    Tanja Trarbach
    BMC Cancer, 17
  • [48] Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma
    Benjamin, David J. J.
    Lythgoe, Mark P. P.
    Rezazadeh, Arash
    BJU INTERNATIONAL, 2023, 131 (06) : 691 - 693
  • [49] UPADACITINIB AS SECOND- AND THIRD-LINE SALVAGE THERAPY FOR REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS
    Hassan, Syed Adeel
    Perry, Courtney
    Flomenhoft, Deborah
    Richardson, Brooks
    Kapur, Neeraj
    Berinstein, Jeffrey
    Barrett, Terrence
    INFLAMMATORY BOWEL DISEASES, 2024, 30
  • [50] Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line
    Leighl, N. B.
    CURRENT ONCOLOGY, 2012, 19 : S52 - S58
12345